CA2118121C - Methods and compositions for the treatment of diseases with interferon while reducing side effects - Google Patents

Methods and compositions for the treatment of diseases with interferon while reducing side effects Download PDF

Info

Publication number
CA2118121C
CA2118121C CA002118121A CA2118121A CA2118121C CA 2118121 C CA2118121 C CA 2118121C CA 002118121 A CA002118121 A CA 002118121A CA 2118121 A CA2118121 A CA 2118121A CA 2118121 C CA2118121 C CA 2118121C
Authority
CA
Canada
Prior art keywords
hepatitis
use according
human leukocyte
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002118121A
Other languages
English (en)
French (fr)
Other versions
CA2118121A1 (en
Inventor
Lawrence M. Blatt
Milton W. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25352556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2118121(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2118121A1 publication Critical patent/CA2118121A1/en
Application granted granted Critical
Publication of CA2118121C publication Critical patent/CA2118121C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002118121A 1992-04-15 1993-04-14 Methods and compositions for the treatment of diseases with interferon while reducing side effects Expired - Lifetime CA2118121C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/868,916 US5372808A (en) 1990-10-17 1992-04-15 Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US07/868,916 1992-04-15
PCT/US1993/004471 WO1993021229A1 (en) 1992-04-15 1993-04-14 Methods and compositions for the treatment of diseases with interferon while reducing side effects

Publications (2)

Publication Number Publication Date
CA2118121A1 CA2118121A1 (en) 1993-10-28
CA2118121C true CA2118121C (en) 2005-08-02

Family

ID=25352556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002118121A Expired - Lifetime CA2118121C (en) 1992-04-15 1993-04-14 Methods and compositions for the treatment of diseases with interferon while reducing side effects

Country Status (26)

Country Link
US (1) US5372808A (OSRAM)
EP (3) EP0641359A4 (OSRAM)
JP (2) JPH07505894A (OSRAM)
KR (1) KR950701350A (OSRAM)
CN (1) CN1098103C (OSRAM)
AT (1) ATE254926T1 (OSRAM)
AU (1) AU683214B2 (OSRAM)
CA (1) CA2118121C (OSRAM)
CZ (1) CZ247194A3 (OSRAM)
DE (1) DE69333321T3 (OSRAM)
DK (1) DK0911033T4 (OSRAM)
ES (1) ES2210864T5 (OSRAM)
HU (1) HU227310B1 (OSRAM)
IL (1) IL105366A (OSRAM)
MX (1) MX9302160A (OSRAM)
NO (1) NO318643B1 (OSRAM)
NZ (1) NZ252871A (OSRAM)
PT (1) PT911033E (OSRAM)
RO (1) RO115700B1 (OSRAM)
RU (1) RU2128056C1 (OSRAM)
SG (1) SG52443A1 (OSRAM)
SK (1) SK284712B6 (OSRAM)
TW (1) TW265265B (OSRAM)
UA (1) UA44223C2 (OSRAM)
WO (1) WO1993021229A1 (OSRAM)
ZA (1) ZA932641B (OSRAM)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
KR100223255B1 (ko) * 1992-02-10 1999-10-15 더글라스 테스타 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
US5789551A (en) * 1993-06-11 1998-08-04 Pestka Biomedical Laboratories, Inc. Human leukocyte interferon Hu-IFN-α001
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
WO1995015177A2 (en) * 1993-12-02 1995-06-08 President And Fellows Of Harvard College Improved efficacy of alpha-helical cytokines
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
JP3104257B2 (ja) * 1995-08-30 2000-10-30 東レ株式会社 心疾患治療剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
WO1997041884A1 (en) 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Method of treatment
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6432398B1 (en) * 1998-09-29 2002-08-13 W. Robert Fleischmann Methods of treating diseased cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
RU2140285C1 (ru) * 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN101099745A (zh) 2000-05-26 2008-01-09 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
TWI228512B (en) 2000-10-25 2005-03-01 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2179000C1 (ru) * 2000-12-21 2002-02-10 Тверская государственная медицинская академия Способ комплексного лечения базалиом кожи
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
MXPA04002915A (es) * 2001-09-28 2004-07-05 Intermune Inc Metodo para tratar infeccion de virus de hepatitis c en pacientes que han fallado el tratamiento.
WO2003030923A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
WO2003061728A2 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
ES2586668T5 (es) 2003-05-30 2024-11-12 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
JP2007501185A (ja) 2003-07-25 2007-01-25 イデニクス（ケイマン）リミテツド Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
CA2535902A1 (en) 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
ES2473622T3 (es) * 2003-08-28 2014-07-07 Superlab Far East Limited Usos de interferones con estructura espacial alterada
GEP20084560B (en) 2003-10-14 2008-12-10 Ntermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
AU2004309390B2 (en) * 2003-12-22 2011-06-02 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
EP2286791B1 (en) 2003-12-30 2014-03-26 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
MXPA06013412A (es) 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
MY167668A (en) 2005-03-09 2018-09-21 Superlab Far East Ltd Uses of recombinant super-compound interferons
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1888633A4 (en) 2005-05-18 2010-01-27 Maxygen Inc UNFOLDED INTERFERON ALPHA POLYPEPTIDE
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP1924594A2 (en) 2005-07-25 2008-05-28 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2008004754A (es) 2005-10-11 2009-03-02 Intermune Inc Compuestos y metodos para inhibir la replicacion viral de hepatitis c.
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102753563A (zh) * 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Sciences, Inc. Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
CN105517540B (zh) 2013-08-27 2019-08-23 吉利德制药有限责任公司 两种抗病毒化合物的复方制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8302778A1 (es) † 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
SE8502430L (sv) † 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
ATE78262T1 (de) † 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
ES2128348T3 (es) * 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
DE69333321D1 (de) 2004-01-08
KR950701350A (ko) 1995-03-23
CN1081909A (zh) 1994-02-16
ATE254926T1 (de) 2003-12-15
HUT70216A (en) 1995-09-28
EP0911033A2 (en) 1999-04-28
AU4293493A (en) 1993-11-18
RU2128056C1 (ru) 1999-03-27
SK124794A3 (en) 1995-04-12
SK284712B6 (sk) 2005-09-08
DK0911033T4 (da) 2010-03-22
UA44223C2 (uk) 2002-02-15
EP0911033B2 (en) 2009-11-18
DK0911033T3 (da) 2004-03-29
NO318643B1 (no) 2005-04-25
CZ247194A3 (en) 1995-04-12
CA2118121A1 (en) 1993-10-28
KR100321467B1 (OSRAM) 2008-11-13
IL105366A0 (en) 1993-08-18
MX9302160A (es) 1994-05-31
TW265265B (OSRAM) 1995-12-11
HK1018595A1 (en) 1999-12-30
DE69333321T2 (de) 2004-09-16
JPH07505894A (ja) 1995-06-29
ZA932641B (en) 1993-10-22
EP0911033B1 (en) 2003-11-26
ES2210864T3 (es) 2004-07-01
WO1993021229A1 (en) 1993-10-28
US5372808A (en) 1994-12-13
IL105366A (en) 1999-11-30
ES2210864T5 (es) 2010-03-09
JP2005029561A (ja) 2005-02-03
HU227310B1 (en) 2011-03-28
NZ252871A (en) 1997-08-22
DE69333321T3 (de) 2010-03-18
EP0641359A4 (en) 1995-10-04
EP1419782A1 (en) 2004-05-19
AU683214B2 (en) 1997-11-06
PT911033E (pt) 2004-04-30
RO115700B1 (ro) 2000-05-30
HU9402979D0 (en) 1995-02-28
SG52443A1 (en) 1998-09-28
NO943901L (no) 1994-10-14
EP0641359A1 (en) 1995-03-08
EP0911033A3 (en) 1999-05-19
CN1098103C (zh) 2003-01-08
NO943901D0 (no) 1994-10-14

Similar Documents

Publication Publication Date Title
CA2118121C (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
HU883981D0 (en) Process for the production of medical preparations with antiviral or antibacterial effect
IE892061L (en) Therapeutic nucleosides
GEP20002297B (en) Alpha-Substituted Pyrimidine-Thioalhyl and Alkyl-Ether Compounds, Method for Treatment of Individual Infected with the Immunodeficiency Virus
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
PT814828E (pt) Metodo de fabrico de um agente terapeutico para a regeneracao de oligodendrocitos
EP0344643B1 (en) Antiviral pharmaceutical composition
Harrison et al. Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment [see comments]
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
IL107818A (en) Pharmaceutical compositions for treating viral infections by conjunctive therapy with acylovir-like compounds and a 2'-(halo) methylene nucleoside analog
JPH039882B2 (OSRAM)

Legal Events

Date Code Title Description
EEER Examination request